Yujun Wang

Dr. Yujun Wang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in Cells
Verified
Journal Article
Open access
PDF file
WWWei Wen
Wei Wen
EMEmily Marcinkowski
Emily Marcinkowski
DLDavid Luyimbazi
David Luyimbazi
TLThehang Luu
Thehang Luu
QXQuanhua Xing
Quanhua Xing
JYJohn Yim
John Yim
Unlike other breast cancer subtypes, patients with triple negative breast cancer (TNBC) have poor outcomes and no effective targeted therapies, leaving an unmet need for therapeutic targets. Efforts to profile these tumors have revealed the PI3K/AKT/mTOR pathway as a potential target. Activation of this pathway also contributes to resistance to anti-cancer agents, including microtubule-targeting agents. Eribulin is one such microtubule-targeting agent that is beneficial in treating taxane and anthracycline refractory breast cancer. In this study, we compared the effect of eribulin on the PI3K/AKT/mTOR pathway with other microtubule-targeting agents in TNBC. We found that the phosphorylation of AKT was suppressed by eribulin, a microtubule depolymerizing agent, but activated by paclitaxel, a microtubule stabilizing agent. The combination of eribulin and everolimus, an mTOR inhibitor, resulted in an increased reduction of p-S6K1 and p-S6, a synergistic inhibition of cell survival in vitro, and an enhanced suppression of tumor growth in two orthotopic mouse models. These findings provide a preclinical foundation for targeting both the microtubule cytoskeleton and the PI3K/AKT/mTOR pathway in the treatment of refractory TNBC.

26 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SSStephanie N Shishido
Stephanie N Shishido
BCBaishali Chaudhuri
Baishali Chaudhuri
VMVidur Mushran
Vidur Mushran
KIKena Ihle
Kena Ihle
YWYujun Wang
Yujun Wang
Peter KuhnPeter Kuhn
Peter Kuhn
Background/Objectives: Leptomeningeal disease (LMD) is among the most severe complications of metastatic breast cancer, with median survival measured in weeks. Definitive diagnosis relies on neuroimaging and cerebrospinal fluid (CSF) cytology, which carries a false-negative rate of 40–50% at a single lumbar puncture. Improved tools for detecting and characterizing tumor cells across systemic and central nervous system (CNS) compartments are urgently needed. Methods: We applied an enrichment-free, fluorescence whole-slide imaging (fWSI)-based liquid biopsy platform to ante-mortem and post-mortem peripheral blood (PB) and CSF from five patients with metastatic breast cancer and confirmed or suspected LMD, collected through the City of Hope LEGACY warm autopsy program. Circulating tumor cells (CTCs) were classified by immunophenotype (cytokeratin [CK], vimentin [VIM], CD45/CD31) and morphology. Select cells underwent single-cell copy number variation (CNV) profiling by low-pass whole-genome sequencing. Results: Across 23 samples (11 PB, 12 CSF), we identified marked compartmental heterogeneity in CTC burden, phenotype, and genomic architecture. In the one patient (Patient 1) sampled across all four ventricular-to-cisternal CSF sites, CTC frequency declined from proximal to distal compartments (11.4% in the right lateral ventricle to 0.6% at the foramen magnum), a single-patient observation consistent with a proximal-to-distal gradient. Patients with active, untreated LMD showed high CSF CTC incidence with both epithelial and mesenchymal phenotypes, whereas the two patients receiving intrathecal therapy each showed low or absent CSF CTCs; given the small numbers involved and a plausible technical confound in a third patient, we interpret this association cautiously. Single-cell CNV profiling of CSF-derived CTCs across patients with active LMD revealed highly concordant chromosomal aberration profiles, 100% of CK+ CSF CTCs analyzed carried chromosomal aberrations, consistent with, though not formally establishing, expansion of a genomically evolved subclone within the leptomeningeal compartment; PB-derived cells showed substantially greater heterogeneity. In the two patients with paired post-mortem arterial and venous PB, arterial blood showed higher total rare cell counts in both, and higher CK-positive CTC incidence in one (1425.73 vs. undetectable epi.CTC/mL); the other showed the reverse for this specific metric. Conclusions: Enrichment-free, multi-compartment liquid biopsy reveals a regionally heterogeneous and biologically structured landscape in breast cancer LMD not resolvable by conventional cytology or single-site venous sampling. These findings are consistent with a hypothesis-generating model in which the leptomeningeal space acts as a selective niche for clonally convergent tumor expansion. They also point to the potential of regionally resolved CTC profiling for monitoring LMD treatment response in future, larger cohorts.

31 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YWYujun Wang
Yujun Wang
RURyan Urak
Ryan Urak
CCClara Jinnette Chen
Clara Jinnette Chen
MSMartha Salas
Martha Salas
CBChristine E Brown
Christine E Brown
LFLisa Feldman
Lisa Feldman
Background/Objectives: Interleukin-13 receptor alpha 2 (IL13Rα2), expressed in more than 75% of glioblastomas (GBM), is a promising chimeric antigen receptor (CAR) T cell target. We investigated how microenvironmental stresses regulate IL13Rα2 expression and whether extracellular vesicle (EV)-mediated antigen transfer modulates CAR T cell killing. Methods: Patient-derived brain tumor and other GBM cell lines were exposed to hypoxia, desferrioxamine (DFO), or reduced fetal bovine serum (FBS). Western blotting assessed IL13Rα2 expression and recovery following reoxygenation. Fluorescence imaging evaluated EV interactions with recipient cells, and cytotoxicity assays assessed CAR T cell killing. Results: Hypoxia and DFO markedly suppressed IL13Rα2 expression. Exposure to 1% oxygen for 48 h reduced protein levels by 40–70%; expression recovered to near-baseline levels within 48 h of reoxygenation. Reduced FBS concentrations for 48 h also decreased IL13Rα2 expression compared with 10% FBS. Findings suggested potential contributions from ubiquitin-dependent degradation and transcriptional mechanisms. IL13Rα2-expressing EVs showed a slight increase under hypoxia. Fluorescence imaging confirmed that IL13Rα2-containing EVs attached to or entered recipient GBM cells within hours. EV-mediated antigen transfer increased CAR T cell killing by 3–5%. Conclusions: Hypoxia and nutrient availability dynamically regulate IL13Rα2 expression, while EVs can transfer the antigen between GBM cells and modestly enhance CAR T cell killing. These findings highlight reversible antigen modulation and EV-mediated antigen redistribution as mechanisms that could inform strategies to overcome antigen escape and improve immune targeting in GBM.